Georges Gemayel, Ph.D., Interim CEO & Chair of the Board


Dr. Georges Gemayel has over 30 years of experience in the pharmaceutical industry, including management and executive positions in the U.S., Europe and the Middle East. Dr. Gemayel currently serves on the board of directors of Supernus Pharmaceuticals, Inc., and is the chair of the boards of Dynacure, OxThera AB, Enterome SA, and Orphazyme A/S. Previously, Dr. Gemayel served as Executive Chair of FoldRx Pharmaceuticals and of Syndexa Pharmaceuticals, as Chair of Dimension Therapeutics and Epitherapeutics and as Director of Prosensa, Raptor Pharmaceuticals, NPS Pharma, Momenta Pharmaceuticals and Adolor.

From 2008 to 2009, Dr. Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company's global therapeutics, transplant, renal and biosurgery businesses. From 1998 to 2003, he held progressively senior roles at Hoffmann La-Roche Ltd. and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis and HIV. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France.

Carl L. Gordon, Ph.D., C.F.A, OrbiMed


Carl L. Gordon is a founding partner and co-head of global private equity at OrbiMed.

He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995.

Carl received his doctorate in molecular biology from the Massachusetts Institute of Technology (1993) and his undergraduate degree from Harvard College (1987). Carl was included on the Forbes Midas List of top venture capital investors in 2014.

David Lubner, Independent Director


David Lubner is an experienced financial professional with tenure in the biotech and pharmaceutical industry. He serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020.

Prior to joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015. In addition he served as a senior leader at ProScript, Inc., where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. He currently serves on the board of Dyne Therapeutics and previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019.

David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.

Tuyen Ong, MBA, M.D., Independent Board Member


Dr. Ong is a board-certified ophthalmologist and biotechnology/pharmaceutical industry management executive. He currently serves as senior vice president and head of the ophthalmology franchise at Biogen.

Dr. Ong served as chief development officer at Nightstar Therapeutics up until its acquisition by Biogen in June 2019. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, and investor and M&A activities. Dr. Ong brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of ophthalmology, genetic and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer.

Dr. Ong holds an M.D. from the University College London and an M.B.A. from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.

Jason Rhodes, Atlas Venture


Jason is a general partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, and Be Biopharma and was previously the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020. Prior to Atlas, he held leadership positions with Epizyme (NASDAQ: EPZM) and Alnylam Pharmaceuticals (NASDAQ: ALNY) and was a founder and general partner with Fidelity Biosciences (now F-Prime Capital), the biotech venture capital arm of Fidelity Investments.

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Jim Tananbaum, Foresite Capital


Jim Tananbaum, MD ’89, MBA ’91, is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm established in 2011 that has approximately $3 billion in assets under management. During the last three decades, Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation, including 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. A four-time Midas List honoree, he currently serves as a member of the Yale University Council and the advisory committee of Yale School of Engineering & Applied Science.


As an undergraduate, Jim attended Yale, where he graduated with a BS and BSEE in applied math and electrical engineering/computer science.  He then earned an MD from Harvard, graduating from the Harvard-MIT Program in Health Sciences and Technology (HST). He also earned an MBA from Harvard while playing rugby.